The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Estimating progression to cirrhosis in chronic hepatitis C virus infection
Abstract
To gain a clearer understanding of the rate of progression to cirrhosis and its determinants in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic studies that incorporated assessment for cirrhosis has been undertaken. Inclusion criteria were more than 20 cases of chronic HCV infection, and information on either age of subjects or duration of infection. Of 145 studies examined, 57 fulfilled the inclusion criteria. Least-squares linear regression was employed to estimate rates of progression to cirrhosis, and to examine for factors associated with more rapid disease progression in 4 broad study categories: 1) liver clinic series (number of studies = 33); 2) posttransfusion cohorts (n = 5); 3) blood donor series (n = 10); and 4) community-based cohorts (n = 9). Estimates of progression to cirrhosis after 20 years of chronic HCV infection were 22% (95% CI, 18%-26%) for liver clinic series, 24% (11%-37%) for posttransfusion cohorts, 4% (1%-7%) for blood donor series, and 7% (4%-10%) for community-based cohorts. Factors that were associated with more rapid disease progression included older age at HCV infection, male gender, and heavy alcohol intake. Even after accounting for these factors, progression estimates were much higher for cross-sectional liver clinic series. Selection biases probably explain the higher estimates of disease progression in this group of studies. Community-based cohort studies are likely to provide a more representative basis for estimating disease progression at a population level. These suggest that for persons who acquire HCV infection in young adulthood, less than 10% are estimated to develop cirrhosis within 20 years. (Hepatology 2001;34:809-816.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M., Hoofnagle, J. H., Manns, M., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,593
The Natural History of Community-Acquired Hepatitis C in the United States
Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272702 · Cited by 1,592
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H., et al. (1990) · Hepatology · doi:10.1002/hep.1840120409 · Cited by 1,217
Clinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A. R., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,198
The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas, D. L., Astemborski, J., Rai, R. M., Anania, F. A., Schaeffer, M., Galai, N., Nolt, K., Nelson, K. E., Strathdee, S. A., Johnson, L., et al. (2000) · JAMA · doi:10.1001/jama.284.4.450 · Cited by 1,073
Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin
Kenny-Walsh, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904223401602 · Cited by 910
Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C
Liang, T. J., Rehermann, B., Seeff, L. B., & Hoofnagle, J. H. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-4-200002150-00008 · Cited by 868
Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis
Seeff, L. B., Buskell-Bales, Z., Wright, E. C., Durako, S. J., Alter, H. J., Iber, F. L., Hollinger, F. B., Gitnick, G., Knodell, R. G., Perrillo, R. P., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272703 · Cited by 672
Cited by
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
Mohd Hanafiah, K., Groeger, J., Flaxman, A. D., & Wiersma, S. T. (2013) · Hepatology · doi:10.1002/hep.26141 · Cited by 2,515
Natural history of chronic hepatitis C
Seeff, L. B. (2002) · Hepatology · doi:10.1053/jhep.2002.36806 · Cited by 1,424
The global burden of hepatitis C
Lavanchy, D. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01934.x · Cited by 1,368
The burden of liver disease in Europe: A review of available epidemiological data
Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D.-C., & Roudot-Thoraval, F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.005 · Cited by 1,341
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
Forns, X. (2002) · Hepatology · doi:10.1016/s0270-9139(02)00107-6 · Cited by 1,125
Epidemiology and natural history of HCV infection
Hajarizadeh, B., Grebely, J., & Dore, G. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.107 · Cited by 994
Self-citationThein, H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008) · Hepatology · doi:10.1002/hep.22375 · Cited by 829
Self-citationCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Massarweh, N. N., & El-Serag, H. B. (2017) · Cancer Control · doi:10.1177/1073274817729245 · Cited by 634
The changing pattern of epidemiology in hepatocellular carcinoma
Nordenstedt, H., White, D. L., & El-Serag, H. B. (2010) · Digestive and Liver Disease · doi:10.1016/s1590-8658(10)60507-5 · Cited by 535
Global Burden of Disease (GBD) for Hepatitis C
The Global Burden of Hepatitis C Working Group (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003258669 · Cited by 488
Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis
Tang, A., Hallouch, O., Chernyak, V., Kamaya, A., & Sirlin, C. B. (2018) · Abdominal Radiology · doi:10.1007/s00261-017-1209-1 · Cited by 480
The global burden of disease attributable to contaminated injections given in health care settings
Hauri, A. M., Armstrong, G. L., & Hutin, Y. J. F. (2004) · International Journal of STD & AIDS · doi:10.1258/095646204322637182 · Cited by 458
Hepatocellular Carcinoma – Epidemiological Trends and Risk Factors
Schütte, K., Bornschein, J., & Malfertheiner, P. (2009) · Digestive Diseases · doi:10.1159/000218339 · Cited by 441
Treatment of Hepatitis C: A Systematic Review
Kohli, A., Shaffer, A., Sherman, A., & Kottilil, S. (2014) · JAMA · doi:10.1001/jama.2014.7085 · Cited by 426
Thein, H.-H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008) · AIDS · doi:10.1097/qad.0b013e32830e6d51 · Cited by 409
Self-citationNatural History of Hepatitis C
Thomas, D. L., & Seeff, L. B. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2005.05.003 · Cited by 402
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Global epidemiology and burden of HCV infection and HCV-related disease
Thrift, A. P., El-Serag, H. B., & Kanwal, F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.176 · Cited by 382
MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Mirza, F., & Canalis, E. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 331
Epidemiology of Hepatocellular Carcinoma
El-Serag, H. B. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70155-0 · Cited by 327
Koh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Kanwal, F., Kramer, J. R., Li, L., Dai, J., Natarajan, Y., Yu, X., Asch, S. M., & El‐Serag, H. B. (2020) · Hepatology · doi:10.1002/hep.31014 · Cited by 319
“8% at 10 years, approaching the risk in community-based cohorts with HCV (estimated ~3%-4% at 10 years following infection).(25) HCC surveillance, with imaging and serological biomarkers, may then be limited to patients with cirrhosis.”
BackgroundEpidemiology of Hepatocellular Carcinoma
Lafaro, K. J., Demirjian, A. N., & Pawlik, T. M. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.09.001 · Cited by 303
Castéra, L., Hézode, C., Roudot-Thoraval, F., Bastie, A., Zafrani, E.-S., Pawlotsky, J.-M., & Dhumeaux, D. (2003) · Gut · doi:10.1136/gut.52.2.288 · Cited by 298
Hepatocellular carcinoma and hepatitis C in the United States
El-Serag, H. B. (2002) · Hepatology · doi:10.1002/hep.1840360710 · Cited by 291
Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview
Rashed, W. M., Kandeil, M. A. M., Mahmoud, M. O., & Ezzat, S. (2020) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-020-0016-x · Cited by 283
Fibrosis and disease progression in hepatitis C
Marcellin, P., Asselah, T., & Boyer, N. (2002) · Hepatology · doi:10.1002/hep.1840360707 · Cited by 267
Hézode, C., Asselah, T., Reddy, K. R., Hassanein, T., Berenguer, M., Fleischer-Stepniewska, K., Marcellin, P., Hall, C., Schnell, G., Pilot-Matias, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60159-3 · Cited by 259
Natural History of Hepatitis C
Lingala, S., & Ghany, M. G. (2015) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2015.07.003 · Cited by 252
van de Laar, T. J., Matthews, G. V., Prins, M., & Danta, M. (2010) · AIDS · doi:10.1097/qad.0b013e32833c11a5 · Cited by 252
George, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.001 · Cited by 213
Linas, B. P., Barter, D. M., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1313 · Cited by 101
Goodgame, B., Shaheen, N. J., Galanko, J., & El-Serag, H. B. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07678.x · Cited by 72
“There is at least one previous systematic review of the literature that addressed the risk of cirrhosis in HCV (5).”
BackgroundHepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy
HALLINAN, R., BYRNE, A., AMIN, J., & DORE, G. J. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03882.x · Cited by 56
Self-citation
Metadata
- Authors
- Freeman, A. J., Dore, G. J., Law, M. G., Thorpe, M., Von Overbeck, J., Lloyd, A. R., Marinos, G., & Kaldor, J. M.
- Venue
- Hepatology
- Published
- 2001-10
- Volume
- 34
- Issue
- 4
- Pages
- 809-816
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2047556186
- Cited by
- 620
- References
- 58
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.